Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
11 mai 2023 07h30 HE
|
Praxis Precision Medicines, Inc.
Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for...
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
11 mai 2023 06h55 HE
|
Praxis Precision Medicines, Inc.
PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider...
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
19 avr. 2023 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
17 avr. 2023 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
06 avr. 2023 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at Upcoming Investor Conferences
03 mars 2023 16h05 HE
|
Praxis Precision Medicines, Inc.
BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
03 mars 2023 07h30 HE
|
Praxis Precision Medicines, Inc.
Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
07 févr. 2023 08h00 HE
|
Praxis Precision Medicines, Inc.
Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9 Topline...
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
13 déc. 2022 16h01 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical...
Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
28 nov. 2022 16h05 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...